The Cluster Headache Market is estimated to be valued at US$ 402.12 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Cluster headache is a rare neurological disorder characterized by recurrent episodes of excruciating unilateral headaches. It is the most severe form of headache disorder. Cluster headache is caused due to inflammation of trigeminal nerve near blood vessels of face and head. Cluster headache are treated using drugs such as triptans, oxygen therapy, corticosteroids, ergotamine derivatives, and others. Biologics such as monoclonal antibodies are emerging as new treatment options for cluster headache.
Market Dynamics:
The cluster headache market is driven by rising prevalence of cluster headache disorder and growing awareness about available treatment options. According to a report published by National Institute of Neurological Disorders and Stroke, cluster headache affects around 0.1% of general population worldwide. Men are 2-3 times more likely to develop cluster headache than women. Another key factor fueling market growth is product approvals and launch of innovative treatment therapies. In 2020, Eli Lilly received FDA approval for gepants medication called Reyvow (lasmiditan) for acute treatment of cluster headache. The drug offers new non-vasoconstrictive option with lower side effects. In addition, increasing research activities for developing biologics to treat cluster headache is also boosting market growth. For instance, ongoing late-stage clinical trials evaluating monoclonal antibodies are exploring long term preventive treatment options for cluster headache.
Segment Analysis
The cluster headache market is segmented into episodic and chronic cluster headaches. The chronic cluster headache segment is dominating the market currently and holds the largest market share. Around 15% of the total cluster headache patient population suffers from chronic cluster headaches that last for more than one year without remission. The chronic cluster headache patients require frequent medical attention and long term medications that drive the growth of this segment.
PEST Analysis
Political: Governments across countries are focusing on increasing healthcare funding and approvals for novel drugs and therapies to treat rare conditions like cluster headaches. Economic: Rising healthcare expenditure and growing disposable income have been fueling the demand for advanced treatment options for cluster headaches. Social: Increasing awareness about various types of headache disorders via social media and patient support groups is encouraging more number of patients to seek proper diagnosis and treatment. Technological: Ongoing research and development activities for developing novel drug delivery systems like injectables and gene therapies holds potential to provide long term relief for cluster headache patients.
Key Takeaways
The Global Cluster Headache Market Growth is expected to witness high, exhibiting CAGR of 6.4% over the forecast period, due to increasing research funding for development of novel therapies.
The United States dominates the global cluster headache market currently and is expected to remain the largest market during the forecast period. High healthcare spending, strong research base, and availability of advanced treatment options drive the US market.
Key players operating in the cluster headache market are Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
